Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2022
OraPharma launches OraFit clear aligner system
Bausch Health and its oral health care business OraPharma announced the U.S. launch of the OraFit custom clear aligner system for correcting misaligned permanent teeth.
2021
Bausch Health announces planned Solta Medical IPO
Bausch Health said it planned to pursue an initial public offering of its medical aesthetics business, Solta Medical. The company said the IPO should take place in the fourth quarter or first half of 2022, depending on market conditions.
2020
Lupin launches generic Apriso in the US
Lupin said it launched the generic version of Bausch Health's Apriso, mesalamine extended-release capsules, in the US market.
2020
Bausch Health prices and upsizes senior notes offering
Bausch Health announced that it had priced and increased the size of its senior notes offering to $1.5 billion in aggregate principal amount, from the previously announced $1.25 billion. The proceeds, together with cash on hand, were expected to fund a conditional redemption of existing notes, prepay 2022 term-loan amortization and cover related costs.
2020
Bausch Health lowers 2020 forecast
Bausch Health lowered its 2020 outlook, reducing its revenue expectation to about US$8 billion from US$8.75 billion and its adjusted earnings expectation to roughly US$3.25 billion from US$3.6 billion.
2020
Bausch Health reports first-quarter 2020 loss
Bausch Health reported a first-quarter loss of US$152 million, compared with a net loss of US$52 million a year earlier.
2020
FDA approves expanded JUBLIA labeling for children
The U.S. Food and Drug Administration approved a supplemental New Drug Application for JUBLIA topical solution, extending its labeled age range to children six years and older.